Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
企業コードALMR
会社名Alamar Biosciences Inc
上場日Apr 17, 2026
最高経営責任者「CEO」Luo (Yuling)
従業員数- -
証券種類Ordinary Share
決算期末- -
本社所在地47071 Bayside Pkwy
都市FREMONT
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94538
電話番号15106269888
ウェブサイトhttps://alamarbio.com
企業コードALMR
上場日Apr 17, 2026
最高経営責任者「CEO」Luo (Yuling)